Zobrazeno 1 - 10
of 35
pro vyhledávání: '"C.M. Nijenhuis"'
Autor:
Daniel Kallin, Marit M. van Buuren, Jessica Kohler, Jonathan McGee, C.M. Nijenhuis, Joost H. van den Berg, Dewi Harjanto, Paul J. Turcott, Janani Sridar, Divya Lenkala, Brian C. McCarthy, Richard B. Gaynor, Michael D. Nelson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Neoantigens are tumor-specific antigens that are important in the anti-tumor immune response. These antigens are not subject to central immune tolerance and are therefore potentially more immunogenic than tumor-associated antigens. NEO-STI
Autor:
Jonathan McGee, Divya Lenkala, Prerna Suri, Gabe S. Sonke, John B. A. G. Haanen, Marit M. van Buuren, Jessica Kohler, Christina M. Arieta, Richard B. Gaynor, C.M. Nijenhuis, Mark DeMario, Brian C. McCarthy, Maarje Rohaan, Susan Hannes, Dewi Harjanto, Daniel Kallin, Paul J. Turcott, Diana Velez, Shirisha Meda
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A212-A212
BackgroundNeoantigens are tumor-specific antigens that are important in the anti-tumor immune response. These antigens are not subject to central immune tolerance and are therefore potentially more immunogenic than tumor-associated antigens. Here, we
Autor:
Christian U. Blank, Hilde Rosing, J.V. van Thienen, Stefanie L. Groenland, N. de Vries, Sofie Wilgenhof, J.B.A.G. Haanen, A. D. R. Huitema, C.M. Nijenhuis, Neeltje Steeghs, Julie M Janssen, J. H. Beijnen
Publikováno v:
Annals of Oncology. 31:S486-S487
Autor:
A. D. R. Huitema, C.M. Nijenhuis, Hilde Rosing, Jan H.M. Schellens, J.B.A.G. Haanen, J.V. van Thienen, Jos H. Beijnen, Christian U. Blank
Publikováno v:
The Journal of Clinical Pharmacology. 57:125-128
Autor:
C.M. Nijenhuis, Christian U. Blank, Johannes V. Van Thienen, Jos H. Beijnen, Serena Marchetti, Jan H.M. Schellens, Alwin D. R. Huitema, Hilde Rosing, John B. A. G. Haanen
Publikováno v:
The Journal of Clinical Pharmacology. 56:1307-1312
Pharmacokinetic monitoring is increasingly becoming an important part of clinical care of tyrosine kinase inhibitor treatment. Vemurafenib is an oral tyrosine kinase inhibitor that inhibits mutated serine/threonine protein kinase B-Raf (BRAF) and is
Autor:
Hitoshi Mizuo, Jos H. Beijnen, Robert S. Jansen, A. C. Dubbelman, David Critchley, Shinki Kawaguchi, Hilde Rosing, Jan H.M. Schellens, C.M. Nijenhuis, Robert Shumaker
Publikováno v:
Investigational New Drugs, 34(3), 300. Kluwer Academic Publishers
Lenvatinib is an oral, multiple receptor tyrosine kinase inhibitor. Preclinical drug metabolism studies showed unique metabolic pathways for lenvatinib in monkeys and rats. A human mass balance study demonstrated that lenvatinib related material is m
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Huixin Yu, C.M. Nijenhuis, Neeltje Steeghs, Jan H.M. Schellens, Alwin D. R. Huitema, Jos H. Beijnen
Publikováno v:
Clinical Pharmacokinetics. 53:305-325
There is accumulating evidence for potential benefits of therapeutic drug monitoring (TDM) in the treatment of cancer with tyrosine kinase inhibitors (TKIs). Relationships between exposure and response (efficacy/toxicity) have been established for se
Publikováno v:
Cancer Treatment Reviews. 39:305-312
In the last few years, several drugs targeting signalling proteins critical for melanoma entered clinical evaluation. In 2011 vemurafenib (Zelboraf®, F. Hoffman-La Roche Ltd.) was approved for BRAF V600-positive melanoma and showed high overall resp
Autor:
G Jamieson, Diane R. Mould, Hilde Rosing, C.M. Nijenhuis, L. Lucas, J A Fox, A. D. R. Huitema, Marja Mergui-Roelvink, Jos H. Beijnen, Jan H.M. Schellens
Publikováno v:
Investigational New Drugs, 35(4), 478. Kluwer Academic Publishers
Background Vosaroxin is a first-in-class anticancer quinolone derivative that is being investigated for patients with relapsed or refractory acute myeloid leukemia (AML). The primary objective of this study was to quantitatively determine the pharmac